Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
19 studies found for:    nivolumab and yervoy | Phase 3
Show Display Options
Rank Status Study
1 Recruiting A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis
Condition: Brain Metastases
Interventions: Drug: Fotemustine;   Drug: Fotemustine and Ipilimumab;   Drug: Ipilimumab and nivolumab
2 Not yet recruiting Efficacy Study of Nivolumab Plus Ipilimumab Against Chemotherapy Standard of Care in Stomach Cancer or Stomach/Esophagus Junction Cancer
Conditions: Gastric Cancer;   Gastroesophageal Junction Cancer
Interventions: Drug: Nivolumab;   Drug: Ipilimumab;   Drug: Oxaliplatin;   Drug: Capecitabine;   Drug: Leucovorin;   Drug: Fluorouracil
3 Active, not recruiting Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)
Condition: Unresectable or Metastatic Melanoma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Biological: Placebo for Nivolumab;   Biological: Placebo for Ipilimumab
4 Recruiting Nivolumab and Ipilimumab With or Without Sargramostim in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Conditions: Recurrent Melanoma of the Skin;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: Sargramostim
5 Recruiting A Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
Condition: Lung Cancer
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Other: Placebo
6 Recruiting Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
7 Recruiting Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
Conditions: Recurrent Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIC Skin Melanoma;   Stage IV Skin Melanoma
Interventions: Drug: Dabrafenib;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Other: Quality-of-Life Assessment;   Drug: Trametinib
8 Recruiting A Study of the Effectiveness and Safety of Nivolumab Compared to Bevacizumab and of Nivolumab With or Without Ipilimumab in Glioblastoma Patients
Condition: Recurrent Glioblastoma
Interventions: Biological: Nivolumab;   Biological: Bevacizumab;   Biological: Ipilimumab
9 Recruiting A Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
Condition: Non-Small Cell Lung Cancer
Interventions: Drug: Nivolumab;   Drug: Ipilimumab;   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Gemcitabine;   Drug: Pemetrexed
10 Active, not recruiting Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Conditions: Advanced Renal Cell Carcinoma;   Metastatic Renal Cell Carcinoma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Drug: Sunitinib
11 Not yet recruiting A Safety Study of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers
Condition: Lung Cancer
Intervention: Drug: Nivolumab in combination with Ipilimumab
12 Not yet recruiting A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Patients With EGFR Mutation, T790M Negative NSCLC Who Have Failed 1L EGFR TKI Therapy
Condition: Non-Small-Cell Lung Carcinoma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Carboplatin
13 Not yet recruiting Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
Condition: Mesothelioma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Drug: Pemetrexed;   Drug: Cisplatin;   Drug: Carboplatin
14 Recruiting Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Study Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Head and Neck Cancer
Interventions: Biological: Nivolumab;   Biological: Ipilimumab;   Drug: Cetuximab/Erbitux;   Drug: Cisplatin/Platinol;   Drug: Carboplatin/Paraplatin;   Drug: Fluorouracil/Adrucil
15 Active, not recruiting Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)
Condition: Melanoma
Interventions: Drug: Ipilimumab;   Drug: Nivolumab;   Other: Placebo matching Ipilimumab;   Other: Placebo matching Nivolumab
16 Recruiting A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma
Condition: Melanoma
Interventions: Biological: Nivolumab 3 mg/kg IV;   Biological: Ipilimumab 1 mg/kg IV;   Biological: Nivolumab 1 mg/kg IV;   Biological: Ipilimumab 3 mg/kg IV
17 Recruiting Nivolumab Combined With Ipilimumab Followed by Nivolumab Monotherapy as First-Line Treatment for Patients With Advanced Melanoma
Condition: Melanoma
Interventions: Drug: Nivolumab;   Drug: Ipilimumab
18 Not yet recruiting A Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Melanoma
Condition: Melanoma
Interventions: Biological: Nivolumab;   Biological: Ipilimumab
19 Recruiting Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
Conditions: Recurrent Squamous Cell Lung Carcinoma;   Stage IV Squamous Cell Lung Carcinoma
Interventions: Drug: Docetaxel;   Biological: Durvalumab;   Drug: Erlotinib Hydrochloride;   Drug: FGFR Inhibitor AZD4547;   Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Drug: Palbociclib;   Biological: Rilotumumab;   Drug: Taselisib

Indicates status has not been verified in more than two years